查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1726370

全球非酒精性脂肪性肝炎生物標記市場：市場規模、佔有率、趨勢分析（按類型、最終用途和地區）、細分市場預測（2025-2030 年）

Non-alcoholic Steatohepatitis Biomarkers Market Size, Share & Trends Analysis Report By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers), By End Use (Pharma & CRO Industry, Hospitals), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

非酒精性脂肪性肝炎生物標記市場成長與趨勢：

根據 Grand View Research 的最新報告，全球非酒精性脂肪性肝炎生物標記市場規模預計到 2030 年將達到 56.8 億美元，預測期內的複合年成長率為 23.3%。

由於肥胖和糖尿病等因素導致非酒精性脂肪性肝炎 (NASH) 盛行率不斷上升，大大推動了對 NASH 生物標記的需求。非酒精性脂肪性肝炎 (NASH) 診斷數量的不斷增加推動了對準確診斷工具的需求。此外，政府和醫療保健部門的舉措提高了人們的認知、早期發現和研究津貼，進一步推動了市場成長。這些努力對於解決日益加重的 NASH 負擔和透過生物標記開發改善疾病管理至關重要。

診斷技術的進步和對早期檢測的日益關注正在推動 NASH 生物標記市場的成長。影像技術和血液生物標記等創新的非侵入性檢測方法可以實現更快、更準確的診斷。早期發現可改善治療效果，因此對監測病情進展的先進生物標記的需求日益增加。因此，醫療保健系統對早期療育的日益重視正在推動市場成長，並有助於提供更好的 NASH 管理解決方案。

人們對 NASH 的認知不斷提高，預計將推動對有效生物標記的需求，從而帶來顯著的市場成長。提高對疾病的認知有助於更早診斷和更好地管理疾病。該領域的擴大研究和開發將有助於發現新的生物標記並提高診斷的準確性和治療策略。這些因素預計將推動對 NASH 生物標記的需求並促進市場擴張。

非酒精性脂肪性肝炎生物標記市場：分析概述

  • 根據類型，血清生物標記部分將在 2024 年佔據市場最大收益佔有率，達到 31.2%。
  • 預計肝纖維化生物標記部分在預測期內將以最快的複合年成長率成長，因為它在評估肝損傷的嚴重程度和進展方面發揮關鍵作用。
  • 根據最終用途，製藥和 CRO 行業預計將在 2024 年佔據最大佔有率，因為它在藥物開發、臨床試驗和生物標記檢驗中發揮重要作用。
  • 由於人們認知的提高和對早期檢測和診斷的需求的增加，診斷實驗室部門將成為 2025 年至 2030 年間成長最快的部門。
  • 預計到 2024 年，北美將佔據最大佔有率，約為 54%，這得益於其先進的醫療基礎設施、對肝病的高度認知以及大量的研究投入。

目錄

第1章 分析方法與範圍

第2章執行摘要

3. 非酒精性脂肪性肝炎生物標記市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 非酒精性脂肪性肝炎生物標記市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL分析

第4章非酒精性脂肪性肝炎生物標記市場：按類型進行的估計和趨勢分析

  • 類型細分儀表板
  • 非酒精性脂肪性肝炎生物標記市場：按類型進行變異分析
  • 全球非酒精性脂肪性肝炎生物標記市場：市場規模和趨勢分析（按類型）（2018-2030 年）
  • 血清生物標記
  • 肝纖維化生物標記
  • 細胞凋亡生物標記
  • 氧化壓力生物標記
  • 其他

5. 非酒精性脂肪性肝炎生物標記市場：依最終用途的估計和趨勢分析

  • 最終用途細分儀表板
  • 非酒精性脂肪性肝炎生物標記市場：依最終用途進行變異分析
  • 全球非酒精性脂肪性肝炎生物標記市場：市場規模和趨勢分析（按最終用途分類）（2018-2030 年）
  • 製藥和CRO行業
  • 醫院
  • 診斷實驗室
  • 學術研究所

6. 非酒精性脂肪性肝炎生物標記市場：各地區預測及趨勢

  • 市場儀表板：按地區
  • 各地區市場佔有率分析（2024 年及 2030 年）
  • 非酒精性脂肪性肝炎生物標記市場：關鍵要點
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • Key Company Heat Map Analysis, 2024
  • 公司簡介
    • GENFIT
    • Prometheus Laboratories
    • Siemens Healthineers AG
    • BioPredictive
    • Quest Diagnostics
    • AstraZeneca
    • Exalenz Bioscience Ltd（meridian bioscience）
    • Labcorp
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
Product Code: GVR-1-68038-518-2

Non-alcoholic Steatohepatitis Biomarkers Market Growth & Trends:

The global non-alcoholic steatohepatitis biomarkers market size is anticipated to reach USD 5.68 billion by 2030 and expand at a CAGR of 23.3% during the forecast period, according to a new report by Grand View Research, Inc. The rising prevalence of Non-alcoholic Steatohepatitis (NASH), fueled by factors such as obesity and diabetes, is significantly driving the demand for NASH biomarkers. The growing diagnosis of NASH drives the demand for accurate diagnostic tools. In addition, government and healthcare initiatives promoting awareness, early detection, and research funding further accelerate market growth. These efforts are crucial in addressing the growing burden of NASH and improving disease management through biomarker development.

Advancements in diagnostic technologies and an increased focus on early detection drive the growth of the NASH biomarkers market. Innovative noninvasive testing methods such as imaging techniques and blood-based biomarkers enable quicker, more accurate diagnoses. Early detection improves treatment outcomes, fueling demand for advanced biomarkers to monitor disease progression. Hence, the growing emphasis of healthcare systems on early intervention impels market growth, helping provide improved solutions for NASH management.

Growing awareness of NASH is expected to propel the demand for effective biomarkers, leading to significant market growth. Increasing recognition of the disease encourages earlier diagnosis and better disease management. Expanding research and development in the field advances the discovery of novel biomarkers, improving diagnostic precision and treatment strategies. These factors are anticipated to drive the demand for NASH biomarkers, contributing to the market expansion.

Non-alcoholic Steatohepatitis Biomarkers Market Report Highlights:

  • On the basis of type, the serum biomarkers segment led the market with the largest revenue share of 31.2% in 2024, attributed to their ability to provide non-invasive, cost-effective, reliable diagnostic options.
  • The hepatic fibrosis biomarkers segment is projected to grow at the fastest CAGR during the forecast period, fueled by their crucial role in assessing the severity and progression of liver damage.
  • On the basis of end use, the pharma & CRO industry segment dominated the market with the largest share in 2024, driven by its critical role in drug development, clinical trials, and biomarker validation.
  • The diagnostic labs segment is set to be the fastest-growing segment from 2025 to 2030 due to increasing awareness and the rising demand for early detection and diagnosis.
  • North America accounted for the largest share of almost 54% in 2024, owing toits advanced healthcare infrastructure, high awareness of liver diseases, and substantial research investments.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. End Use
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and Forecasts Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details of Primary Research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type Outlook
    • 2.2.2. End Use Outlook
    • 2.2.3. Regional Outlook
  • 2.3. Competitive Scenario

Chapter 3. Non-alcoholic Steatohepatitis Biomarkers Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Non-alcoholic Steatohepatitis Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
      • 3.3.2.1. Political Landscape
      • 3.3.2.2. Technological Landscape
      • 3.3.2.3. Economic Landscape

Chapter 4. Non-alcoholic Steatohepatitis Biomarkers Market: Type Estimates & Trend Analysis

  • 4.1. Type Segment Dashboard
  • 4.2. Non-alcoholic Steatohepatitis Biomarkers Market: Type Movement Analysis
  • 4.3. Global Non-alcoholic Steatohepatitis Biomarkers Market Size & Trend Analysis, By Type, 2018 to 2030 (USD Million)
  • 4.4. Serum Biomarkers
    • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5. Hepatic Fibrosis Biomarkers
    • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.6. Apoptosis Biomarkers
    • 4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.7. Oxidative Stress Biomarkers
    • 4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Non-alcoholic Steatohepatitis Biomarkers Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Segment Dashboard
  • 5.2. Non-alcoholic Steatohepatitis Biomarkers Market: End Use Movement Analysis
  • 5.3. Global Non-alcoholic Steatohepatitis Biomarkers Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Million)
  • 5.4. Pharma & CRO Industry
    • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5. Hospitals
    • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6. Diagnostic Labs
    • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.7. Academic Research Institutes
    • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Non-alcoholic Steatohepatitis Biomarkers Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Dashboard
  • 6.2. Regional Market Share Analysis, 2024 & 2030
  • 6.3. Non-alcoholic Steatohepatitis Biomarkers Market by Region: Key Takeaways
  • 6.4. North America
    • 6.4.1. U.S.
      • 6.4.1.1. Key Country Dynamics
      • 6.4.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.4.1.3. Competitive Scenario
      • 6.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Canada
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.4.2.3. Competitive Scenario
      • 6.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Mexico
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.4.3.3. Competitive Scenario
      • 6.4.3.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. U.K.
      • 6.5.1.1. Key Country Dynamics
      • 6.5.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.1.3. Competitive Scenario
      • 6.5.1.4. U.K. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Germany
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.2.3. Competitive Scenario
      • 6.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.3. France
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.3.3. Competitive Scenario
      • 6.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Italy
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.4.3. Competitive Scenario
      • 6.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.5. Spain
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.5.3. Competitive Scenario
      • 6.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Denmark
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.6.3. Competitive Scenario
      • 6.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.7. Sweden
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.7.3. Competitive Scenario
      • 6.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.8. Norway
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.8.3. Competitive Scenario
      • 6.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Japan
      • 6.6.1.1. Key Country Dynamics
      • 6.6.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.1.3. Competitive Scenario
      • 6.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.2. China
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.2.3. Competitive Scenario
      • 6.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.3. India
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.3.3. Competitive Scenario
      • 6.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.4. South Korea
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.4.3. Competitive Scenario
      • 6.6.4.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.5.3. Competitive Scenario
      • 6.6.5.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Thailand
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.6.3. Competitive Scenario
      • 6.6.6.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.7.2.3. Competitive Scenario
      • 6.7.2.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.7.3.3. Competitive Scenario
      • 6.7.3.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.2.3. Competitive Scenario
      • 6.8.2.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.3.3. Competitive Scenario
      • 6.8.3.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.4.3. Competitive Scenario
      • 6.8.4.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.5.3. Competitive Scenario
      • 6.8.5.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/ Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key Company Heat Map Analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. GENFIT
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. Prometheus Laboratories
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Siemens Healthineers AG
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. BioPredictive
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Quest Diagnostics
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. AstraZeneca
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Exalenz Bioscience Ltd (meridian bioscience)
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Labcorp
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Pfizer Inc.
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Bristol-Myers Squibb Company
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Non-alcoholic Steatohepatitis Biomarkers Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 5 Global Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 6 North America Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 8 North America Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 9 U.S. Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 10 U.S Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 11 Canada Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 12 Canada Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 13 Mexico Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 14 Mexico Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 15 Europe Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018 - 2030 (USD Million)
  • Table 16 Europe Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 17 Europe Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 18 U.K. Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 19 U.K. Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 20 Germany Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 21 Germany Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 22 France Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 23 France Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 24 Italy Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 25 Italy Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 26 Spain Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 27 Spain Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 28 Denmark Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 29 Denmark Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 30 Sweden Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 31 Sweden Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 32 Norway Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 33 Norway Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 37 Japan Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 38 Japan Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 39 China Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 40 China Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 41 India Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 42 India Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 43 South Korea Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 44 South Korea Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 45 Australia Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 46 Australia Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 47 Thailand Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 48 Thailand Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 49 Latin America Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018 - 2030 (USD Million)
  • Table 50 Latin America Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 51 Latin America Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 52 Brazil Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 53 Brazil Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 54 Argentina Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 55 Argentina Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 59 South Africa Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 60 South Africa Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 63 UAE Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 64 UAE Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Data Triangulation Techniques
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Primary Interviews
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 QFD Modeling for Market Share Assessment
  • Fig. 8 Market Formulation & Validation
  • Fig. 9 Non-alcoholic Steatohepatitis Biomarkers Market: Market Outlook
  • Fig. 10 Non-alcoholic Steatohepatitis Biomarkers Competitive Insights
  • Fig. 11 Parent Market Outlook
  • Fig. 12 Related/Ancillary Market Outlook
  • Fig. 13 Penetration and Growth Prospect Mapping
  • Fig. 14 Industry Value Chain Analysis
  • Fig. 15 Non-alcoholic Steatohepatitis Biomarkers Market Driver Impact
  • Fig. 16 Non-alcoholic Steatohepatitis Biomarkers Market Restraint Impact
  • Fig. 17 Non-alcoholic Steatohepatitis Biomarkers Market Strategic Initiatives Analysis
  • Fig. 18 Non-alcoholic Steatohepatitis Biomarkers Market: Type Movement Analysis
  • Fig. 19 Non-alcoholic Steatohepatitis Biomarkers Market: Type Outlook and Key Takeaways
  • Fig. 20 Serum Biomarkers Market Estimates and Forecast, 2018 - 2030
  • Fig. 21 Hepatic Fibrosis Biomarkers Market Estimates and Forecast, 2018 - 2030
  • Fig. 22 Apoptosis Biomarkers Market Estimates and Forecast, 2018 - 2030
  • Fig. 23 Oxidative Stress Biomarkers Market Estimates and Forecast, 2018 - 2030
  • Fig. 24 Others Market Estimates and Forecast, 2018 - 2030
  • Fig. 25 Non-alcoholic Steatohepatitis Biomarkers Market: End Use Movement Analysis
  • Fig. 26 Non-alcoholic Steatohepatitis Biomarkers Market: End Use Outlook and Key Takeaways
  • Fig. 27 Pharma & CRO Industry Market, 2018-2030 (USD Million)
  • Fig. 28 Hospitals Market, 2018-2030 (USD Million)
  • Fig. 29 Diagnostic Labs Market, 2018-2030 (USD Million)
  • Fig. 30 Academic Research Institutes Market, 2018-2030 (USD Million)
  • Fig. 31 Global Non-alcoholic Steatohepatitis Biomarkers Market: Regional Movement Analysis
  • Fig. 32 Global Non-alcoholic Steatohepatitis Biomarkers Market: Regional Outlook and Key Takeaways
  • Fig. 33 North America Market Estimates and Forecasts, 2018 - 2030
  • Fig. 34 U. S. Market Estimates and Forecasts, 2018 - 2030
  • Fig. 35 Canada Market Estimates and Forecasts, 2018 - 2030
  • Fig. 36 Mexico Market Estimates and Forecasts, 2018 - 2030
  • Fig. 37 Europe Market Estimates and Forecasts, 2018 - 2030
  • Fig. 38 U. K. Market Estimates and Forecasts, 2018 - 2030
  • Fig. 39 Germany Market Estimates and Forecasts, 2018 - 2030
  • Fig. 40 France Market Estimates and Forecasts, 2018 - 2030
  • Fig. 41 Italy Market Estimates and Forecasts, 2018 - 2030
  • Fig. 42 Spain Market Estimates and Forecasts, 2018 - 2030
  • Fig. 43 Denmark Market Estimates and Forecasts, 2018 - 2030
  • Fig. 44 Sweden Market Estimates and Forecasts, 2018 - 2030
  • Fig. 45 Norway Market Estimates and Forecasts, 2018 - 2030
  • Fig. 46 Asia Pacific Market Estimates and Forecasts, 2018 - 2030
  • Fig. 47 Japan Market Estimates and Forecasts, 2018 - 2030
  • Fig. 48 China Market Estimates and Forecasts, 2018 - 2030
  • Fig. 49 India Market Estimates and Forecasts, 2018 - 2030
  • Fig. 50 South Korea Market Estimates and Forecasts, 2018 - 2030
  • Fig. 51 Australia Market Estimates and Forecasts, 2018 - 2030
  • Fig. 52 Thailand Market Estimates and Forecasts, 2018 - 2030
  • Fig. 53 Latin America Market Estimates and Forecasts, 2018 - 2030
  • Fig. 54 Brazil Market Estimates and Forecasts, 2018 - 2030
  • Fig. 55 Argentina Market Estimates and Forecasts, 2018 - 2030
  • Fig. 56 Middle East & Africa Market Estimates and Forecasts, 2018 - 2030
  • Fig. 57 South Africa Market Estimates and Forecasts, 2018 - 2030
  • Fig. 58 Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
  • Fig. 59 UAE Market Estimates and Forecasts, 2018 - 2030
  • Fig. 60 Kuwait Market Estimates and Forecasts, 2018 - 2030